On August 7, BEONE MEDICINES rose 3.16% in regular trading, trading at 206.0 HKD/share, with turnover of approximately 210 million HKD. The rally follows the company's blockbuster Q2 earnings report released on August 5, which significantly exceeded market expectations.

The company reported Q2 global revenue of USD 1.705 billion, up 30% year-over-year, beating the consensus estimate of USD 1.591 billion. Adjusted earnings per share came in at USD 3.84, surpassing the market consensus of USD 1.44 by 167%. First-half net profit attributable to shareholders reached RMB 3.271 billion, surging 627.1% year-over-year. The company simultaneously raised its full-year revenue guidance to RMB 44.9-46.2 billion, up from the prior range of RMB 43.6-45.2 billion, driven by Brukinsa's leading position in the US market and continued expansion in Europe.

Following the results, multiple investment banks upgraded their outlooks. Citi raised its target price to USD 466, CLSA lifted its HK target to HKD 321.7, Daiwa raised to HKD 265, and Goldman Sachs noted accelerating commercial momentum. National Gold Securities maintained a Buy rating, citing the company's dominant global Biopharma position and significant commercialization inflection point.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)